Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood Within Just 12 Minutes

By HospiMedica International staff writers
Posted on 10 Feb 2021
A new rapid COVID-19 test to detect coronavirus antibodies beats the enzyme linked immunosorbent assay (ELISA) method in delivering results within just 12 minutes, marking a milestone in the development of immunological diagnostics.

An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. More...
The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.

The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.

In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.

“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”

“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”

Related Links:
University of Paraná
University of Tübingen



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.